Clinical Trial Update: Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes

View source ↗

Summary

A completed trial evaluated Levemir (insulin detemir) in patients with inadequately controlled Type 1 or Type 2 diabetes. The sponsor was Novo Nordisk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Levemir (insulin detemir)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Status: COMPLETED